Smallpox Clinical Trial
Official title:
VHA Clinicians and Bioterror Events: Interactive Web-based Learning
Verified date | April 2015 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
Our 4-year project uses public domain software and content developed by a University of Alabama at Birmingham (UAB) team and updates, refines, and tailors it to the unique clinician populations and electronic educational applications of VAMCs We are testing an innovative, web-based intervention adapted specifically for the VA to increase syndromic recognition, treatment, and post-exposure prophylaxis of biological warfare agents at multiple VA sites via a randomized controlled trial (RCT). Ultimately, we will disseminate the intervention throughout the entire VA system.
Status | Completed |
Enrollment | 15 |
Est. completion date | September 2007 |
Est. primary completion date | September 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: Clinicians at participating facilities who work in a primary care setting (ED, MOD, general medicine, primary care, or CBOC). Exclusion Criteria: Facilities will be excluded from the project that 1)choose not to participate, or 2)do not have the minimum number of clinicians needed. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Country | Name | City | State |
---|---|---|---|
United States | New Mexico VA Health Care System, Albuquerque, NM | Albuquerque | New Mexico |
United States | VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor | Michigan |
United States | Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA | Bedford | Massachusetts |
United States | Birmingham VA Medical Center, Birmingham, AL | Birmingham | Alabama |
United States | VA Loma Linda Healthcare System, Loma Linda, CA | Loma Linda | California |
United States | Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Nashville | Tennessee |
United States | Phoenix VA Health Care System, Phoenix, AZ | Phoenix | Arizona |
United States | Syracuse VA Medical Center, Syracuse, NY | Syracuse | New York |
United States | James A. Haley Veterans' Hospital, Tampa, FL | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development | University of Alabama at Birmingham |
United States,
Abdolrasulnia M, Strasser S, Pryor E, Terndrup T, Weissman NW, Williams M, Heck E, Casebeer L. Spatial Patterns Representing the Geographic Impact of Physician Participation in an Online CME Bioterrorism Course Following the Anthrax Events of 2001. Medinf
Bennett NL, Casebeer LL, Kristofco RE, Strasser SM. Physicians' Internet information-seeking behaviors. J Contin Educ Health Prof. 2004 Winter;24(1):31-8. — View Citation
Casebeer LL, Strasser SM, Spettell CM, Wall TC, Weissman N, Ray MN, Allison JJ. Designing tailored Web-based instruction to improve practicing physicians' preventive practices. J Med Internet Res. 2003 Jul-Sep;5(3):e20. Epub 2003 Sep 25. — View Citation
Filoromo C, Macrina D, Pryor E, Terndrup T, McNutt SD. An innovative approach to training hospital-based clinicians for bioterrorist attacks. Am J Infect Control. 2003 Dec;31(8):511-4. — View Citation
O'Byrne WT, Terndrup TE, Kiefe CI, Weissman NW. A Primer on Biological Weapons for the Clinician, Part I. Johns Hopkins Advanced Studies in Medicine. 2003 Feb 1; 3:75-86.
O'Byrne WT, Terndrup TE, Kiefe CI, Weissman NW. A Primer on Biological Weapons for the Clinician, Part II. Johns Hopkins Advanced Studies in Medicine. 2003 Mar 1; 3:157-167.
Terndrup T, Nafziger S, Weissman N, Casebeer L, Pryor E. Online bioterrorism continuing medical education: development and preliminary testing. Acad Emerg Med. 2005 Jan;12(1):45-50. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The outcome measure will be performance on post-test administered immediately and at 3 months and 6 months post intervention. Performance on the post-test administered at three months will be considered the main outcome of the study. | 3 months | No | |
Secondary | The 6-month tests will be given to demonstrate the sustainability of the intervention (prevention of decay effect). | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05976100 -
Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years
|
Phase 1 | |
Completed |
NCT01540929 -
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
|
||
Completed |
NCT00258947 -
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
|
Phase 2 | |
Completed |
NCT00189969 -
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
|
Phase 1 | |
Terminated |
NCT00053508 -
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
|
Phase 2 | |
Completed |
NCT01317238 -
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
|
Phase 3 | |
Completed |
NCT01056770 -
Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers
|
Phase 3 | |
Completed |
NCT00998543 -
A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)
|
Phase 2 | |
Terminated |
NCT00282581 -
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
|
Phase 1 | |
Withdrawn |
NCT00389103 -
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
|
Phase 1 | |
Completed |
NCT00133575 -
ACAM 3000 MVA at Harvard Medical School
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00103584 -
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT00050505 -
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
|
Phase 2 | |
Completed |
NCT05846243 -
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
|
Phase 2/Phase 3 | |
Completed |
NCT05935917 -
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
|
Phase 1 | |
Completed |
NCT00082446 -
Combination Study With MVA BN and Dryvax
|
Phase 1 | |
Completed |
NCT00038987 -
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
|
Phase 1/Phase 2 | |
Completed |
NCT05762523 -
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
|
Phase 1 | |
Completed |
NCT04971109 -
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day
|
Phase 3 | |
Completed |
NCT00646152 -
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
|
Phase 1 |